众兴菌业(002772) - 2020 Q1 - 季度财报

Financial Performance - Revenue for Q1 2020 was CNY 366,584,750.64, representing a 19.20% increase compared to CNY 307,543,510.25 in the same period last year[9] - Net profit attributable to shareholders was CNY 74,652,655.18, up 10.89% from CNY 67,323,222.85 year-on-year[9] - Net profit excluding non-recurring items reached CNY 69,248,684.55, an 18.24% increase from CNY 58,567,759.87 in the previous year[9] - Basic earnings per share increased by 20.25% to CNY 0.2179 from CNY 0.1812 in the previous year[9] - Operating profit for the quarter was ¥77,863,041.53, compared to ¥67,779,398.38 in the same period last year, reflecting a growth of approximately 14.8%[52] - Net profit attributable to the parent company was ¥74,652,655.18, an increase from ¥67,323,222.85, which is a rise of about 10.5%[52] - The company recorded a total comprehensive income of CNY 13,679,886.77 for the quarter, compared to CNY 10,264,879.84 in the same period last year, representing an increase of about 33.5%[57] Cash Flow - Operating cash flow for the period was CNY 140,871,191.94, reflecting a 7.10% increase from CNY 131,530,749.45 in the same quarter last year[9] - Cash received from other operating activities in Q1 2020 was 11.94 million CNY, a decrease of 52.91% year-over-year, due to fewer government subsidies received[19] - Cash paid for other operating activities in Q1 2020 was 9.35 million CNY, an increase of 74.95% year-over-year, primarily due to unexpected compensation payments[19] - The net cash flow from investing activities was negative at CNY -172,556,845.52, compared to a positive CNY 10,415,063.36 in the previous year, indicating a significant decline[60] - Cash flow from financing activities generated a net inflow of CNY 293,669,013.40, down from CNY 592,499,436.46 in the previous year, reflecting a decrease of approximately 50.4%[61] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,366,483,508.50, a 7.05% increase from CNY 5,012,915,611.36 at the end of the previous year[9] - The total liabilities of the company were CNY 2,716,380,944.14, compared to CNY 2,410,791,004.22, marking an increase of around 12.66%[44] - The company's equity attributable to shareholders rose to CNY 2,647,116,980.02 from CNY 2,599,482,132.26, which is an increase of about 1.83%[45] - The total current assets reached CNY 2,120,628,195.49, up from CNY 1,820,155,000.10, indicating an increase of about 16.52%[42] - The total cash and cash equivalents increased to CNY 1,226,498,982.47 from CNY 975,903,148.67, reflecting a growth of approximately 25.67%[42] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 35,420[13] - The company repurchased a total of 13,291,116 shares, accounting for 3.61% of the total share capital, with a total transaction amount of approximately 91.08 million CNY[22] - The company plans to repurchase shares with a budget of 100 million to 200 million CNY, with a repurchase price range of 1.00 to 9.00 CNY per share[21] Research and Development - R&D expenses for Q1 2020 amounted to 1.93 million CNY, a significant increase of 321.61% year-over-year, attributed to higher technical service fees[18] - Research and development expenses increased to ¥1,925,272.67 from ¥456,646.44, showing a significant rise of approximately 321.5%[51] Financial Management - The company has entrusted financial management with a total amount of 73,400,000 yuan, with an unexpired balance of 72,700,000 yuan[31] - The entrusted financial management includes 38,000,000 yuan from self-owned funds and 35,400,000 yuan from raised funds[31] - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[28] - The company has not reported any overdue or unrecoverable amounts in entrusted financial management[34] Compliance and Audit - The company did not conduct an audit for the Q1 2020 report, indicating it was unaudited[72] - The company has no violations regarding external guarantees during the reporting period[35] - The company has not engaged in derivative investments during the reporting period[34]